Myriad Genetics (NASDAQ:MYGN) Announces Earnings Results, Beats Expectations By $0.03 EPS
Myriad Genetics (NASDAQ:MYGN) Announces Earnings Results, Beats Expectations By $0.03 EPS
Myriad Genetics (NASDAQ:MYGN – Get Rating) released its quarterly earnings results on Thursday. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.01 by $0.03, Briefing.com reports. The company had revenue of $179.30 million for the quarter, compared to the consensus estimate of $170.05 million. Myriad Genetics had a negative net margin of 2.62% and a negative return on equity of 3.44%. Myriad Genetics's revenue was down 5.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.03 earnings per share. Myriad Genetics updated its FY22 guidance to $(0.10)-$0.00 EPS and its FY 2022 guidance to -$0.10-0 EPS.
週四,納斯達克(MYGN-GET Rating)發佈了季度收益報告。據Briefing.com報道,該公司公佈本季度每股收益(EPS)為0.04美元,比分析師普遍預期的0.01美元高出0.03美元。該公司本季度營收為1.793億美元,而市場普遍預期為1.705億美元。Myriad Genetics的淨利潤率為負2.62%,股本回報率為負3.44%。Myriad Genetics的收入同比下降了5.3%。去年同期,該公司每股收益為0.03美元。Myriad Genetics將其22財年每股收益指引更新為0.10-0.00美元,將2022財年每股收益指引更新為-0.10-0美元。
Myriad Genetics Price Performance
數不勝數的基因產品性價比
Shares of MYGN opened at $27.46 on Friday. The company's fifty day simple moving average is $20.69 and its 200-day simple moving average is $22.87. Myriad Genetics has a twelve month low of $16.02 and a twelve month high of $36.95.
上週五,MYGN的股價開盤報27.46美元。該公司的50日簡單移動均線切入位為20.69美元,200日簡單移動均線切入位為22.87美元。Myriad Genetics的12個月低點為16.02美元,12個月高位為36.95美元。
Analyst Upgrades and Downgrades
分析師升級和下調評級
A number of equities research analysts recently issued reports on MYGN shares. Cowen set a $25.00 price target on shares of Myriad Genetics in a research note on Tuesday, July 19th. The Goldman Sachs Group decreased their price target on shares of Myriad Genetics from $26.00 to $23.00 and set a "sell" rating on the stock in a research note on Tuesday, April 19th. StockNews.com downgraded shares of Myriad Genetics from a "buy" rating to a "hold" rating in a research note on Wednesday, July 13th. SVB Leerink increased their target price on shares of Myriad Genetics from $26.00 to $30.00 and gave the company a "market perform" rating in a research note on Friday. Finally, TheStreet downgraded shares of Myriad Genetics from a "c-" rating to a "d+" rating in a research note on Friday, June 3rd.
一些股票研究分析師最近發佈了關於MYGN股票的報告。考恩在7月19日星期二的一份研究報告中為Myriad Genetics的股票設定了25.00美元的目標價。4月19日,週二,高盛夫婦在一份研究報告中將Myriad Genetics的股票目標價從26.00美元下調至23.00美元,並對該股設定了“賣出”評級。在7月13日星期三的一份研究報告中,StockNews.com將Myriad Genetics的股票評級從“買入”下調至“持有”。SVB Leerink在週五的一份研究報告中將Myriad Genetics的目標價從26.00美元上調至30.00美元,並給予該公司“市場表現”的評級。最後,華爾街在6月3日星期五的一份研究報告中將Myriad Genetics的股票評級從“c-”下調至“d+”。
Insider Transactions at Myriad Genetics
Myriad Genetics的內幕交易
Institutional Inflows and Outflows
機構資金流入和流出
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of Montreal Can grew its holdings in Myriad Genetics by 147.9% during the 1st quarter. Bank of Montreal Can now owns 65,458 shares of the company's stock worth $1,687,000 after acquiring an additional 39,052 shares in the last quarter. MetLife Investment Management LLC boosted its holdings in shares of Myriad Genetics by 55.6% in the 1st quarter. MetLife Investment Management LLC now owns 42,669 shares of the company's stock valued at $1,075,000 after buying an additional 15,255 shares in the last quarter. Hsbc Holdings PLC bought a new stake in shares of Myriad Genetics in the 1st quarter valued at about $648,000. American Century Companies Inc. boosted its holdings in shares of Myriad Genetics by 22.3% in the 1st quarter. American Century Companies Inc. now owns 16,607 shares of the company's stock valued at $418,000 after buying an additional 3,027 shares in the last quarter. Finally, Walleye Capital LLC bought a new stake in shares of Myriad Genetics in the 1st quarter valued at about $399,000. 97.44% of the stock is currently owned by institutional investors.
對衝基金和其他機構投資者最近增持或減持了該業務的股份。蒙特利爾銀行在第一季度對Myriad Genetics的持股增加了147.9%。蒙特利爾銀行在上個季度增持了39,052股後,現在可以持有65,458股該公司股票,價值1,68.7萬美元。大都會人壽投資管理有限責任公司在第一季度增持了Myriad Genetics的股票55.6%。大都會人壽投資管理有限責任公司目前持有42,669股該公司股票,價值1,075,000美元,上一季度又購買了15,255股。滙豐控股在第一季度購買了Myriad Genetics的新股,價值約64.8萬美元。美國世紀公司第一季度增持Myriad Genetics股票22.3%。美國世紀公司目前持有16,607股該公司股票,價值41.8萬美元,上一季度又購買了3,027股。最後,Walleye Capital LLC在第一季度購買了Myriad Genetics的新股,價值約39.9萬美元。97.44%的股票目前由機構投資者持有。
Myriad Genetics Company Profile
萬得基因公司簡介
(Get Rating)
(獲取評級)
Myriad Genetics, Inc, a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
Myriad Genetics,Inc.是一家基因測試和精密藥物公司,在美國和國際上開發基因測試並將其商業化。該公司提供分子診斷測試,用於腫瘤學、婦女和心理健康應用。它提供了MyRisk遺傳性癌症測試,這是一種評估遺傳性癌症風險的DNA測序測試;BRAC分析CDX種系伴隨診斷測試,這是一種DNA測序測試,有助於確定轉移性乳腺癌、卵巢癌、轉移性胰腺癌或轉移性前列腺癌患者的治療方案,這些患者具有有害或疑似有害的種系BRCA變異;以及MyChoice CDX伴生診斷測試,這是一種腫瘤測試,可以確定卵巢癌患者的同源重組缺陷狀態。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Myriad Genetics (MYGN)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- Why Apple Could Be At All-Time Highs By Year End
- 免費獲取StockNews.com關於Myriad遺傳學的研究報告(MYGN)
- MarketBeat:回顧中的一週8/1-8/5
- 如何利用高貝塔係數股票最大化你的投資利潤
- 克羅諾斯集團(Cronos Group Inc.)營收上升,是時候收購了嗎?
- Beyond Meat不是沒有希望,而且它很便宜
- 蘋果為何可能在年底創下歷史新高
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《Myriad Genetics Daily》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊,接收Myriad Genetics和相關公司的最新新聞和分析師評級的每日摘要。